About Us

BirchBioMed is a pioneering clinical-stage biopharmaceutical company developing innovative treatments for diseases with high unmet medical needs, such as organ fibrosis, scarring, skin disorders, and certain autoimmune conditions like type 1 diabetes. Leveraging groundbreaking technologies, we are committed to transforming patient care and improving outcomes.

Our Mission

At BirchBioMed, we are committed to transforming lives by developing groundbreaking therapies for organ fibrosis, specific autoimmune disorders, and severe skin disorders. With a focus on innovative treatments like FS2 (kynurenic acid, or KynA) and AI-001, a novel, proprietary combination of KynA with antigen-presenting cells (APCs), we strive to deliver curative solutions that offer new hope to millions of patients worldwide.
Mission
person filling a well plate with a pipette with a close up of cells as the background image
group of people in a meeting room in a modern building

Leadership

BirchBioMed’s senior leadership team and board of directors consist of industry veterans with decades of experience in the biopharmaceutical sector. With a deep passion for scientific innovation, they are dedicated to advancing cutting-edge therapies that address fibrosis, autoimmune diseases, and severe skin disorders.

Leadership

Grants

Our technology has received more than $6 million in grants and in-kind funding from prestigious institutions, underscoring the strength and potential of our science. These awards reflect the confidence leading organizations have in our innovative approach to treating fibrosis, specific autoimmune disorders, and related conditions.

Grants
abstract collage of scientific diagrams and a neucleus/molecule model